Trial details
Two Stereotactic MRI-Guided Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: 2SMART
Official title: Two Stereotactic MRI-Guided Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer
Principal Investigator: Dr. Andrew Loblaw
Cancer type: Genitourinary
Cancer location: Genitourinary
Disease stage: Early Cancer
Trial phase:
Intervention:
Registration #:
Inclusion criteria: 1. Informed consent obtained 2. Men >18 years 3. Histologically confirmed prostate adenocarcinoma (centrally reviewed) 4. Favorable risk prostate cancer, defined as clinical stage T1-2c, Gleason Sum 7, and PSA 20 ng/mL (patients can have only one of T2c, Gleason Sum 7 and PSA 10-20 ng/ml) Exclusion criteria: 1. Androgen deprivation therapy (LHRH-agonists or antiandrogens) > 6 mo 2. Prior pelvic radiotherapy 3. Anticoagulation medication (if unsafe to discontinue for gold seed insertion) 4. Diagnosis of bleeding diathesis 5. Large prostate (>90cm3) on imaging 6. Immunosuppressive medications 7. Inflammatory bowel disease 8. Presence of a hip prosthesis
